Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea.
Ocular adnexal lymphoma (OAL) is a mostly extranodal marginal zone lymphoma (EMZL). Recent findings have suggested an association between Chlamydia psittaci (Cp) infection and OAL. We sought to confirm this issue and to analyze the clinicopathologic characteristics of OAL in Korea. Between 1993 and 2004, 33 OAL cases were identified at the Asan Medical Center, Seoul, Korea. DNA was extracted from paraffin-embedded tissues, and touchdown enzyme time release polymerase chain reaction was performed to identify three Chlamydia species (Cp, C. tracomatis, and C. pneumoniae). The same procedures were also performed in 21 samples from patients with non-neoplastic ocular adnexal disease (NNOAD). All OAL cases were EMZL. Cp DNA was detected in 26/33 (79%) OAL samples compared with 5/21 (23%) NNOAD samples (P < 0.001). With a median follow-up of 38.5 months (range: 1-105 months), the 5-year progression-free survival (PFS) and overall survival (OS) rates of OAL patients were 72% and 93%, respectively. Clinicopathologic characteristics, recurrence rate, PFS, and OS were not associated with Cp infection. Our study demonstrates an association between OAL and Cp infection in Korea, suggesting that Cp plays a role as a causative antigen in Korean OAL patients.
Yoo
Changhoon
C
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ryu
Min-Hee
MH
Huh
Jooryung
J
Park
Ji Hyun
JH
Kang
Hye Jin
HJ
Ahn
Hyo Sook
HS
Lee
Yongjae
Y
Kim
Myoung Joon
MJ
Lee
Hyoungnam
H
Kim
Tae Won
TW
Chang
Heung Moon
HM
Lee
Jae-Lyun
JL
Kang
Yoon-Koo
YK
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D016022:Case-Control Studies; D002691:Chlamydophila psittaci / Q000235:genetics / Q000302:isolation & purification*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004269:DNA, Bacterial / Q000302:isolation & purification; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005134:Eye Neoplasms / Q000150:complications / Q000235:genetics / Q000382:microbiology* / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D007723:Korea / Q000453:epidemiology; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy / Q000235:genetics / Q000382:microbiology* / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D016133:Polymerase Chain Reaction; D011241:Prednisone / Q000008:administration & dosage; D009956:Psittacosis / Q000150:complications* / Q000453:epidemiology; D012189:Retrospective Studies; D055502:Secondary Prevention; D017422:Sequence Analysis, DNA; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D004269:DNA, Bacterial; D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D011241:Prednisone